|
Chronic kidney disease stage 5
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The creatinine- and cystatin C-based rapid progressions were associated with increased risk of ESRD (HR = 2.22 [1.57-3.13], HR = 2.03 [1.44-2.86], respectively; all p < 0.001).
|
31185945 |
2019 |
|
Chronic kidney disease stage 5
|
0.090 |
Biomarker
|
disease |
BEFREE |
A neonatal CysC >3.0 mg/L predicted progression to ESRD while a nadir SCr >0.6 mg/dL predicted progression to CKD 3-5 with the highest specificity and sensitivity by ROC-AUC analysis (<i>P</i> < 0.0001).
|
31139603 |
2019 |
|
Chronic kidney disease stage 5
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Laboratory blood tests including serum creatinine, serum urea, cystatin-C, serum parathyroid hormone (PTH), calcium and phosphorus levels, hemoglobin and hematocrit were performed in all ESRD patients close to the time of the MR examination.
|
29974312 |
2018 |
|
Chronic kidney disease stage 5
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
According to our results, although serum KIM-1, NGAL, OPN, MMP-9, and urine MMP-9, urine KIM-1 do not appear to be ideal markers to evaluate renal injury in the early period of obesity, the serum levels of cystatin C and urine NGAL, urine OPN can be used as a good marker for assessing the renal effect of obesity which can lead end stage renal disease in pediatric population.
|
30035656 |
2018 |
|
Chronic kidney disease stage 5
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Levels of cystatin C in low- and high-flux hemodialysis in children with end-stage renal disease.
|
28417217 |
2017 |
|
Chronic kidney disease stage 5
|
0.090 |
Biomarker
|
disease |
BEFREE |
Declines in mGFR, eGFR<sub>cr</sub>, eGFR<sub>BTP</sub>, and the average of 4 filtration markers (creatinine, cystatin C, BTP, and B2M) were consistently associated with progression to ESRD.
|
28648303 |
2017 |
|
Chronic kidney disease stage 5
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
In the Atherosclerosis Risk in Communities Study (n = 13,277 from 4 US communities), we used structural equation modeling to estimate the association between serum 1,5-AG levels and end-stage renal disease (ESRD) from baseline (1990-1992) through 2013 with adjustment for demographics, risk factors, a latent variable for glycemia (diabetes status, fasting glucose, glycated hemoglobin (HbA1c), fructosamine, glycated albumin), and a latent variable for kidney function (creatinine, cystatin C, β2-microglobulin).
|
28535187 |
2017 |
|
Chronic kidney disease stage 5
|
0.090 |
Biomarker
|
disease |
BEFREE |
Using a cross-sectional analysis from the eGFR Study of 654 Indigenous Australians at high risk of ESKD, eGFR was calculated using the CKD-EPI equations for serum creatinine (eGFRcr), cystatin C (eGFRcysC) and combined creatinine and cystatin C (eGFRcysC+cr).
|
27894952 |
2017 |
|
Chronic kidney disease stage 5
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Folate and residual glomerular filtration estimated by cystatin C and creatinine levels were two independent determinants of tHcy in ESRD patients.
|
11592445 |
2001 |